Loading
ELVN-002 is an experimental oral small-molecule kinase inhibitor from Enliven Therapeutics, in phase 1 trials for HER2-mutant non-small cell lung cancer, HER2-positive breast cancer and HER2-positive gastric and colorectal cancer; development is paused.
ELVN-002 is an oral small-molecule kinase inhibitor (irreversible) from Enliven Therapeutics. A selective, irreversible HER2 inhibitor active against HER2 mutations including exon 20 insertions. Its furthest stage is phase 1, for HER2-mutant non-small cell lung cancer, HER2-positive breast cancer and HER2-positive gastric and colorectal cancer. ClinicalTrials.gov registers it in 2 studies linked below. Company: "In May 2025, we made the decision to explore strategic alternatives for ELVN-002 so that we could prioritize relcobatinib." Both phase 1 trials active, not recruiting. Whether it works in people has not been established unless a trial below reports it.
A selective, irreversible HER2 inhibitor active against HER2 mutations including exon 20 insertions. Connects to HER2.
1.ELVN-002 slips into a pocket on HER2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ELVN-002" OR ABSTRACT:"ELVN-002") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ELVN-002, not a curated reading list.
Shares HER2-mutant non-small-cell lung cancer, HER2 and the tag pipeline.
Shares HER2-mutant non-small-cell lung cancer, HER2 and the tag pipeline.
Shares Enliven Therapeutics and the tag pipeline.
Shares Enliven Therapeutics and the tag pipeline.
Shares HER2-mutant non-small-cell lung cancer, HER2 and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.
Shares Enliven Therapeutics and the tag pipeline.
Shares HER2, Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/